Erratum: Department of Error (The Lancet (2016) 388(10055) (2023–2038) (S0140673616301738) (10.1016/S0140-6736(16)30173-8));Rheumatoid arthritis

The Lancet

Volumn 388, Issue 10055, 2016, Pages 2023-2038

  Smolen, Josef S ^a,b   Aletaha, Daniel ^a   McInnes, Iain B ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital Vienna   (Austria)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSESSMENT; GENETICS; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; INCIDENCE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE;

EID: 84964773927     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30794-2     Document Type: Erratum

References (168)

1. 1 Aletaha, D, Neogi, T, Silman, A, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
2. 2 Smolen, JS, Aletaha, D, Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheum 11 (2015), 276–289.
3. 3 Nam, JL, Ramiro, S, Gaujoux-Viala, C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73 (2014), 516–528.
4. 4 Gaujoux-Viala, C, Nam, J, Ramiro, S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73 (2014), 510–515.
5. 5 Ramiro, S, Gaujoux-Viala, C, Nam, JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73 (2014), 529–535.
6. 6 Stoffer, MA, Schoels, M, Smolen, JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75 (2016), 16–22.
7. 7 Cross, M, Smith, E, Hoy, D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73 (2014), 1316–1322.
8. 8 Kitas, GD, Gabriel, SE, Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70 (2011), 8–14.
9. 9 Sokka, T, Kautiainen, H, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther, 12, 2010, R42.
10. 10 Silman, AJ, Pearson, JE, Pincus, T, et al. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4:suppl 3 (2002), S265–S272.
11. 11 Alamanos, Y, Voulgari, PV, Drosos, AA, Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36 (2006), 182–188.
12. 12 Silman, AJ, MacGregor, AJ, Thomson, W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32 (1993), 903–907.
13. 13 Jiang, X, Frisell, T, Askling, J, et al. To what extent is the familial risk of rheumatoid arthritis explained by established rheumatoid arthritis risk factors?. Arthritis Rheumatol 67 (2015), 352–362.
14. 14 Frisell, T, Hellgren, K, Alfredsson, L, Raychaudhuri, S, Klareskog, L, Askling, J, Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. Ann Rheum Dis 75 (2016), 183–189.
15. 15 Roberson, ED, Bowcock, AM, Psoriasis genetics: breaking the barrier. Trends Genet 26 (2010), 415–423.
16. 16 Okada, Y, Wu, D, Trynka, G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506 (2014), 376–381.
17. 17 Gregersen, PK, Silver, J, Winchester, RJ, The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (1987), 1205–1213.
18. 18 Viatte, S, Plant, D, Han, B, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA 313 (2015), 1645–1656.
19. 19 Lenz, TL, Deutsch, AJ, Han, B, et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nat Genet 47 (2015), 1085–1090.
20. 20 Barra, L, Pope, J, Bessette, L, Haraoui, B, Bykerk, V, Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford) 50 (2011), 311–316.
21. 21 Nell-Duxneuner, V, Machold, K, Stamm, T, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 69 (2010), 169–174.
22. 22 Klein, K, Gay, S, Epigenetics in rheumatoid arthritis. Curr Opin Rheumatol 27 (2015), 76–82.
23. 23 Liu, Y, Aryee, MJ, Padyukov, L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 31 (2013), 142–147.
24. 24 Baxter, D, McInnes, IB, Kurowska-Stolarska, M, Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol Cell Biol 90 (2012), 288–292.
25. 25 Bluml, S, Bonelli, M, Niederreiter, B, et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum 63 (2011), 1281–1288.
26. 26 Silman, AJ, Newman, J, MacGregor, AJ, Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 39 (1996), 732–735.
27. 27 Klareskog, L, Malmstrom, V, Lundberg, K, Padyukov, L, Alfredsson, L, Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 23 (2011), 92–98.
28. 28 Millar, K, Lloyd, SM, McLean, JS, et al. Personality, socio-economic status and inflammation: cross-sectional, population-based study. PLoS One, 8, 2013, e58256.
29. 29 Callahan, LF, Pincus, T, Education, self-care, and outcomes of rheumatic diseases: further challenges to the “biomedical model” paradigm. Arthritis Care Res 10 (1997), 283–288.
30. 30 Scher, JU, Littman, DR, Abramson, SB, Review: microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol 68 (2016), 35–45.
31. 31 Wegner, N, Wait, R, Sroka, A, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 62 (2010), 2662–2672.
32. 32 Ebringer, A, Wilson, C, HLA molecules, bacteria and autoimmunity. J Med Microbiol 49 (2000), 305–311.
33. 33 Smolen, JS, Aletaha, D, Koeller, M, Weisman, M, Emery, P, New therapies for the treatment of rheumatoid arthritis. Lancet 370 (2007), 1861–1874.
34. 34 McInnes, IB, Schett, G, The pathogenesis of rheumatoid arthritis. N Engl J Med 365 (2011), 2205–2219.
35. 35 Honda, K, Littman, DR, The microbiome in infectious disease and inflammation. Annu Rev Immunol 30 (2012), 759–795.
36. 36 Scher, JU, Ubeda, C, Artacho, A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 67 (2015), 128–139.
37. 37 Aletaha, D, Alasti, F, Smolen, JS, Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther, 17, 2015, 229.
38. 38 Gonzalez, A, Icen, M, Kremers, HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 35 (2008), 1009–1014.
39. 39 van Gaalen, FA, van Aken, J, Huizinga, TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50 (2004), 2113–2121.
40. 40 Zhao, X, Okeke, NL, Sharpe, O, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther, 10, 2008, R94.
41. 41 Sabharwal, UK, Vaughan, JH, Fong, S, Bennett, PH, Carson, DA, Curd, JG, Activation of the classical pathway of complement by rheumatoid factors. Assessment by radioimmunoassay for C4. Arthritis Rheum 25 (1982), 161–167.
42. 42 Anquetil, F, Clavel, C, Offer, G, Serre, G, Sebbag, M, IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol 194 (2015), 3664–3674.
43. 43 Schellekens, GA, de Jong, BA, van den Hoogen, FH, van de Putte, LB, van Venrooij, WJ, Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101 (1998), 273–281.
44. 44 Girbal-Neuhauser, E, Durieux, JJ, Arnaud, M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro) filaggrin by deimination of arginine residues. J Immunol 162 (1999), 585–594.
45. 45 Reynisdottir, G, Olsen, H, Joshua, V, et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann Rheum Dis, 2015 published online Nov 3. DOI:10.1136/annrheumdis-2015-208216.
46. 46 Nielen, MM, van Schaardenburg, D, Reesink, WH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50 (2004), 380–386.
47. 47 Rombouts, Y, Willemze, A, van Beers, JJ, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 75 (2016), 578–585.
48. 48 Rombouts, Y, Ewing, E, van de Stadt, LA, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74 (2015), 234–241.
49. 49 Kerkman, PF, Fabre, E, van der Voort, EI, et al. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis, 2015 published online June 1. DOI:10.1136/annrheumdis-2014-207182.
50. 50 Harre, U, Georgess, D, Bang, H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122 (2012), 1791–1802.
51. 51 Bohler, C, Radner, H, Smolen, JS, Aletaha, D, Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis 72 (2013), 241–244.
52. 52 Shi, J, van Veelen, PA, Mahler, M, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 13 (2014), 225–230.
53. 53 Sokolove, J, Johnson, DS, Lahey, LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 66 (2014), 813–821.
54. 54 Klarenbeek, PL, de Hair, MJ, Doorenspleet, ME, et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 71 (2012), 1088–1093.
55. 55 James, EA, Rieck, M, Pieper, J, et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol 66 (2014), 1712–1722.
56. 56 de Hair, MJ, Zijlstra, IA, Boumans, MJ, et al. Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Ann Rheum Dis 71 (2012), 1911–1912.
57. 57 Mavers, M, Ruderman, EM, Perlman, H, Intracellular signal pathways: potential for therapies. Curr Rheum Rep 11 (2009), 378–385.
58. 58 Smolen, JS, Steiner, G, Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2 (2003), 473–488.
59. 59 Humby, F, Kelly, S, Hands, R, et al. Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials. Arthritis Rheumatol 67 (2015), 2601–2610.
60. 60 Feldmann, M, Maini, SR, Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223 (2008), 7–19.
61. 61 Pettit, AR, Ji, H, von Stechow, D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159 (2001), 1689–1699.
62. 62 Redlich, K, Hayer, S, Ricci, R, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 110 (2002), 1419–1427.
63. 63 Martel-Pelletier, J, Welsch, DJ, Pelletier, JP, Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15 (2001), 805–829.
64. 64 Kraan, MC, Versendaal, H, Jonker, M, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 41 (1998), 1481–1488.
65. 65 Hayer, S, Redlich, K, Korb, A, Hermann, S, Smolen, J, Schett, G, Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum 56 (2007), 79–88.
66. 66 Raza, K, Saber, TP, Kvien, TK, Tak, PP, Gerlag, DM, Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 71 (2012), 1921–1923.
67. 67 Gerlag, DM, Raza, K, van Baarsen, LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 71 (2012), 638–641.
68. 68 Radner, H, Neogi, T, Smolen, JS, Aletaha, D, Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 73 (2014), 114–123.
69. 69 Hurd, ER, Extraarticular manifestations of rheumatoid arthritis. Semin Arthritis Rheum 8 (1979), 151–176.
70. 70 Baecklund, E, Iliadou, A, Askling, J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006), 692–701.
71. 71 Listing, J, Kekow, J, Manger, B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74 (2015), 415–421.
72. 72 Choi, HK, Hernan, MA, Seeger, JD, Robins, JM, Wolfe, F, Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002), 1173–1177.
73. 73 Jacobsson, LT, Turesson, C, Nilsson, JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007), 670–675.
74. 74 Patatanian, E, Thompson, DF, A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 22 (2002), 1157–1162.
75. 75 Lee, HH, Song, IH, Friedrich, M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156 (2007), 486–491.
76. 76 van der Heijde, DM, Van't Hof, MA, van Riel, PL, van Leeuwen, MA, van Rijswijk, MH, van de Putte, LB, Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51 (1992), 177–181.
77. 77 Welsing, PM, van Gestel, AM, Swinkels, HL, Kiemeney, LA, van Riel, PL, The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44 (2001), 2009–2017.
78. 78 Felson, DT, Anderson, JJ, Boers, M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995), 727–735.
79. 79 Felson, DT, Smolen, JS, Wells, G, et al. American College Of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70 (2011), 404–413.
80. 80 Prevoo, MLL, van't Hof, MA, Kuper, HH, van de Putte, LBA, van Riel, PLCM, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995), 44–48.
81. 81 Smolen, JS, Breedveld, FC, Schiff, MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42 (2003), 244–257.
82. 82 Aletaha, D, Nell, VPK, Stamm, T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res 7 (2005), R796–R806.
83. 83 Aletaha, D, Martinez-Avila, J, Kvien, TK, Smolen, JS, Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 71 (2012), 1190–1196.
84. 84 Radner, H, Smolen, JS, Aletaha, D, Remission in rheumatoid arthritis: benefit over low disease activity in patient reported outcomes and costs. Arthritis Res Ther, 16, 2014, R56.
85. 85 Smolen, JS, Han, C, Van der Heijde, DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis 68 (2009), 823–827.
86. 86 Welsing, PM, Landewe, RB, van Riel, PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 50 (2004), 2082–2093.
87. 87 Smolen, JS, van der Heijde, DMFM, St Clair, EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 54 (2006), 702–710.
88. 88 Pincus, T, Swearingen, CJ, Bergman, M, Yazici, Y, RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35 (2008), 2136–2147.
89. 89 Smolen, JS, Landewe, R, Breedveld, FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
90. 90 Singh, JA, Saag, KG, Bridges, SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68 (2016), 1–25.
91. 91 Kavanaugh, A, Fleischmann, RM, Emery, P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72 (2013), 64–71.
92. 92 Thiele, K, Huscher, D, Bischoff, S, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1194–1199.
93. 93 Makinen, H, Kautiainen, H, Hannonen, P, Sokka, T, Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 64 (2005), 1410–1413.
94. 94 Fleischmann, R, van der Heijde, D, Koenig, AS, et al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?. Ann Rheum Dis 74 (2015), 1132–1137.
95. 95 Balsa, A, de Miguel, E, Castillo, C, Peiteado, D, Martin-Mola, E, Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 49 (2010), 683–690.
96. 96 Smolen, JS, Aletaha, D, Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 63 (2011), 43–52.
97. 97 Smolen, JS, Collaud Basset, S, Boers, M, et al. for the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis, 2016 published online April 1. DOI:10.1136/annrheumdis-2016-209429.
98. 98 Fleischmann, R, Kremer, J, Cush, J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
99. 99 Smolen, JS, Aletaha, D, Gruben, D, et al. Remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheum, 64(suppl), 2012, S334.
100. 100 Smolen, JS, Breedveld, FC, Burmester, GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 (2016), 3–15.
101. 101 Food and Drug Administration. Guidance for industry—rheumatoid arthritis: Developing drug products for treatment. Draft Guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM354468.pdf, May 2013 (accessed Jan 18, 2016).
102. 102 van der Heijde, D, Simon, L, Smolen, J, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 47 (2002), 215–218.
103. 103 Jimenez-Boj, E, Nobauer-Huhmann, I, Hanslik-Schnabel, B, et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 56 (2007), 1118–1124.
104. 104 Mandl, P, Balint, PV, Brault, Y, et al. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. Arthritis Rheum 64 (2012), 1272–1282.
105. 105 Sakellariou, G, Scire, CA, Verstappen, SM, Montecucco, C, Caporali, R, In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 72 (2013), 245–249.
106. 106 Dale, J, Striling, A, McInnes, IB, Porter, D, Targeting ultrasound remission in early rheumatoid arthritis—results of the Taser study. Arthritis Rheum 65:suppl (2013), S338–S339.
107. 107 Nordberg Lena, B, Lie, E, Lillegraven, S, et al. Ultrasonography versus clinical examination in early DMARD-naive rheumatoid arthritis—a comparative study of synovitis on the individual joint level. Arthritis Rheumatol, 67(suppl 10), 2015, 162 (abstr).
108. 108 Terslev, L, Torp-Pedersen, S, Qvistgaard, E, von der, RP, Bliddal, H, Doppler ultrasound findings in healthy wrists and finger joints. Ann Rheum Dis 63 (2004), 644–648.
109. 109 Fries, JF, Spitz, P, Kraines, RG, Holman, HR, Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980), 137–145.
110. 110 Aletaha, D, Alasti, F, Smolen, JS, Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis, 2015 published online Sept 29. DOI:10.1136/annrheumdis-2015-208324.
111. 111 Kirwan, JR, The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333 (1995), 142–146.
112. 112 Smolen, JS, van der Heijde, D, Machold, KP, Aletaha, D, Landewe, R, Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73 (2014), 3–5.
113. 113 Verschueren, P, De, CD, Corluy, L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74 (2015), 27–34.
114. 114 de Jong, PH, Hazes, JM, Han, HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 73 (2014), 1331–1339.
115. 115 Nam, JL, Villeneuve, E, Hensor, EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73 (2014), 75–85.
116. 116 Goekoop-Ruiterman, YP, De Vries-Bouwstra, JK, Allaart, CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005), 3381–3390.
117. 117 Wassenberg, S, Rau, R, Steinfeld, P, Zeidler, H, Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005), 3371–3380.
118. 118 Dougados, M, Combe, B, Cantagrel, A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58 (1999), 220–225.
119. 119 van der Heijde, DM, van Riel, PL, Nuver-Zwart, IH, Gribnau, FW, van de Putte, LB, Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 333 (1989), 1036–1038.
120. 120 Rau, R, Herborn, G, Menninger, H, Sangha, O, Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41 (2002), 196–204.
121. 121 Ward, JR, Williams, JF, Egger, MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 26 (1983), 1303–1315.
122. 122 O'Dell, JR, Mikuls, TR, Taylor, TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369 (2013), 307–318.
123. 123 Capell, HA, Madhok, R, Porter, DR, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 66 (2007), 235–241.
124. 124 Smolen, JS, Aletaha, D, Keystone, E, Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. Arthritis Rheum 52 (2005), 2975–2983.
125. 125 Landewe, RB, Smolen, JS, Weinblatt, ME, et al. Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. Ann Rheum Dis 73 (2014), 1755–1760.
126. 126 Burmester, GR, Rigby, WF, van Vollenhoven, RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis, 2015 published online Oct 28. DOI:10.1136/annrheumdis-2015-207628.
127. 127 Winthrop, KL, Siegel, JN, Jereb, J, Taylor, Z, Iademarco, MF, Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum 52 (2005), 2968–2974.
128. 128 Patakas, A, Ji, RR, Weir, W, et al. Abatacept inhibition of T cell priming in mice by induction of a unique transcriptional profile that reduces their ability to activate antigen-presenting cells. Arthritis Rheumatol 68 (2016), 627–638.
129. 129 Bonelli, M, Ferner, E, Goschl, L, et al. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum 65 (2013), 599–607.
130. 130 Schoels, M, Aletaha, D, Smolen, JS, Wong, JB, Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71 (2012), 1303–1308.
131. 131 Smolen, JS, Kay, J, Matteson, EL, et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 73 (2014), 1811–1818.
132. 132 Smolen, JS, Aletaha, D, Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 72 (2013), 3–6.
133. 133 Burmester, GR, Mariette, X, Montecucco, C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 66 (2007), 732–739.
134. 134 De, SR, Frati, E, Nargi, F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-α versus methotrexate-anti-TNF-alpha. Clin Rheumatol 29 (2010), 517–524.
135. 135 Breedveld, FC, Weisman, MH, Kavanaugh, AF, et al. The PREMIER study—a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006), 26–37.
136. 136 Klareskog, L, van der Heijde, D, de Jager, JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004), 675–681.
137. 137 Dougados, M, Kissel, K, Conaghan, PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73 (2014), 803–809.
138. 138 Kaneko, Y, Atsumi, T, Tanaka, Y, et al. Comparison of adding tocilizumab to methrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis, 2016 published online Jan 5. DOI:10.1136/annrheumdis-2015-208426.
139. 139 Gabay, C, Emery, P, van Vollenhoven, R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
140. 140 Jones, G, Sebba, A, Gu, J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69 (2010), 88–109.
141. 141 Weinblatt, ME, Schiff, M, Valente, R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65 (2013), 28–38.
142. 142 Manders, SH, Kievit, W, Adang, E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther, 17, 2015, 134.
143. 143 Tak, PP, Rigby, WF, Rubbert-Roth, A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70 (2011), 39–46.
144. 144 O'Shea, JJ, Schwartz, DM, Villarino, AV, Gadina, M, McInnes, IB, Laurence, A, The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66 (2015), 311–328.
145. 145 Lee, EB, Fleischmann, R, Hall, S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
146. 146 Taylor, PC, Keystone, EC, van der Heijde, D, et al. Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study. Arthritis Rheum, 67(suppl 10), 2015, L2 (abstr).
147. 147 Genovese, MC, Kremer, J, Zamani, O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374 (2016), 1243–1252.
148. 148 Smolen, JS, Nash, P, Durez, P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381 (2013), 918–929.
149. 149 Emery, P, Burmester, GR, Bykerk, VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74 (2015), 19–26.
150. 150 Smolen, JS, Emery, P, Ferraccioli, GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis, 2014 published online Jan 15. DOI:10.1136/annrheumdis-2013-204632.
151. 151 Listing, J, Strangfeld, A, Kary, S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005), 3403–3412.
152. 152 Hauser, SL, Waubant, E, Arnold, DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 (2008), 676–688.
153. 153 Mohan, N, Edwards, ET, Cupps, TR, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 44 (2001), 2862–2869.
154. 154 Nard, FD, Todoerti, M, Grosso, V, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol 7 (2015), 344–361.
155. 155 Strangfeld, A, Hierse, F, Rau, R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther, 12, 2010, R5.
156. 156 Ostensen, M, Forger, F, Management of RA medications in pregnant patients. Nat Rev Rheumatol 5 (2009), 382–390.
157. 157 Verstappen, SM, King, Y, Watson, KD, Symmons, DP, Hyrich, KL, Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70 (2011), 823–826.
158. 158 Raja, H, Matteson, EL, Michet, CJ, Smith, JR, Pulido, JS, Safety of tumor necrosis factor inhibitors during pregnancy and breastfeeding. Transl Vis Sci Technol, 1, 2012, 6.
159. 159 Gotestam, SC, Hoeltzenbein, M, Tincani, A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75 (2016), 795–810.
160. 160 Flint, J, Panchal, S, Hurrell, A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology, 2016 published online Jan 10.
161. 161 Ducreux, J, Durez, P, Galant, C, et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol 66 (2014), 15–23.
162. 162 Ortea, I, Roschitzki, B, Ovalles, JG, et al. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics 77 (2012), 372–382.
163. 163 Semerano, L, Romeo, PH, Boissier, MC, Metabolomics for rheumatic diseases: has the time come?. Ann Rheum Dis 74 (2015), 1325–1326.
164. 164 Combe, B, Landewe, R, Lukas, C, et al. Eular recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 (2006), 34–45.
165. 165 Grigor, C, Capell, H, Stirling, A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004), 263–269.
166. 166 Gullick, NJ, Oakley, SP, Zain, A, et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology (Oxford) 51 (2012), 759–761.
167. 167 Bakker, MF, Jacobs, JW, Welsing, PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156 (2012), 329–339.
168. 168 Smolen, JS, Emery, P, Fleischmann, R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383 (2014), 321–332.